Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (1842)	5/25/2005 12:01:31 PM
From: Robohogs	Read Replies (1) \| Respond to of 2173

What write makes most sense here? Thoughts? Jon

To: richardred who wrote (1842)	5/26/2005 11:08:39 AM
From: richardred	Read Replies (1) \| Respond to of 2173

LILLY HAS IT RISK SPREAD OUT! "Our strategic alliance with Eli Lilly in the field of diabetes, cardiovascular diseases and endocrine disorders is at once our largest and over the past three years most productive collaborations. We are excited about the multiple significant new oral therapeutics emerging from the outstanding joint efforts of LillylLigand scientists beginning with LY929, which hold great promise for patients with diabetes and cardiovascular disease. We are also pleased with the hard work and great progress of LillylLigand scientific and business teams towards making the alliance management structure our most effective." David E. Robinson Chairman of the Board, President and Chief Executive Officer Ligand Pharmaceuticals, Inc Jose Caro, Lilly"Our collaboration with Ligand has produced an innovative research and drug development platform built on highly validated drug targets. I have the deepest respect for the nuclear receptor expertise of our Ligand colleagues and have no doubt that as a team with Lilly's drug hunters, we will discover and develop important new treatments for patients with unmet medical needs." Jose Caro Vice President, Endocrine Research and Clinical Development Eli Lilly and Company Lilly and Ligand collaborated to discover and develop products based upon Ligand's intracellular receptor technology. The collaboration focused on products with broad applications across metabolic diseases, including diabetes, obesity, dislipidemia, insulin resistance and cardiovascular diseases associated with insulin resistance and obesity. The collaboration enabled both companies to expand their research expertise in the field of intracellular receptors. Intracellular receptors (IRs) are members of a family of hormone-activated proteins that act inside the cell. Activated IRs control gene expression to maintain and restore balanced physiologic function. Drugs that mimic or block hormone action are useful in treating a variety of diseases that result from hormonal and other imbalances. lilly.com